2020-04-29
NextCell Pharma AB publishes its interim report for September 2019 - February 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports
Second quarter (2019-12-01 until 2020-02-29)
· Operating income amounted to SEK 1 364 645 (435 051).
· Operating result amounted to SEK -4 228 449 (-3 552 444).
· Earnings per share* amounted to SEK -0,22 (-0,31).
· Cash and bank amounted to SEK 10 700 725 (6 886 879).
· Solidity** amounted to 80,2 (85,0) %.
First six month (2019-09-01
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports
Second quarter (2019-12-01 until 2020-02-29)
· Operating income...
Read moreRead more2020-03-20
NextCell in discussions about patients with covid-19
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans.
“We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell.
"We advise against speculative share purchases in the
NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans.
“We would like to emphasize that this informa...
Read moreRead more2020-03-11
The stem cell company NextCell Pharma is preparing for a pivotal phase III trial
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11.
NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will
NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11.
NextCell Pharma is currently running two parallel trials with ProTrans (...
Read moreRead more2020-02-21
The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem
The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem
The NIBSC is a UK based entity and a global leader when it comes to...
Read moreRead more2020-02-10
Participates in innovation projects for cell-based products
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies.
The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies.
The Centre for Advanced M...
Read moreRead more2020-02-04
NextCell to present its progress at Swiss Nordic Bio 2020
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich.
Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company w...
Read moreRead more2020-01-31
Interim Report 1 2019/2020
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019.
“NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31.
First quarter (2019-09-01 until 2019-11-30)
· Operating income amounted to SEK 1 222 087 (73 745).
· Operating result amounted to SEK -3 755 926 (-5 440 809).
· Earnings per share* amounted to SEK -0,20 (-0,38).
· Cash and bank
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019.
“NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Com...
Read moreRead more2019-12-11
Extended permission from the Medical Products Agency
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years.
The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials.
In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale dist...
Read moreRead more